Last updated on September 2018

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults


Brief description of study

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.

Detailed Study Description

To compare the safety and efficacy of VL-2397 to standard first-line treatment for invasive aspergillosis in immunocompromised adults with acute leukemia or recipients of an allogeneic hematopoietic cell transplant (allo-HCT).

Clinical Study Identifier: NCT03327727

Contact Investigators or Research Sites near you

Start Over

Aprile Osborn, RN

Medical College of Georgia at Augusta University
Augusta, GA United States
  Connect »

Shelbie Martin

The University of Texas Health Science Center - Houston
Houston, TX United States
  Connect »

Robie A Zent, BSN, RN, ...

Christiana Care Health Services, Department of Medicine
Newark, DE United States
  Connect »

Casey Dahl, MBS

University of Minnesota, Department of Medicine
Minneapolis, MN United States
  Connect »

Kate Trigg, MPH, CCRC

UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases
Sacramento, CA United States
  Connect »

Tracy Reed

Hamilton Health Sciences, Infectious Disease Research
Hamilton, ON Canada
  Connect »

Valerie Tanghe

General Hospital Saint-Jan, Department of Hematology
Brugge, Belgium
  Connect »

Melissa D Garner, BSN, RN

University of Alabama at Birmingham Hospital, Division of Infectious Diseases
Birmingham, AL United States
  Connect »

Susmita Jain

DMC Harper University Hospital
Detroit, MI United States
  Connect »

Cherise Athay

Fred Hutchinson Cancer Research Center (FHCRC)
Seattle, WA United States
  Connect »